INTRODUCTION
============

Viral egress and replication rely on a complex interplay between viral and cellular proteins. During their replication cycle, viruses, notably lentiviruses, have to face several levels of the host immune defense mechanisms and must counteract these barriers to persist and disseminate in the host. Understanding the mechanisms underlying lentiviruses evasion from host antiviral activities has been the focus of many studies of the past decades. Not only did they contribute to major advances in the characterization of host strategies to repress viral replication, notably by the identification of antiviral cellular proteins such as APOBEC3G, SAMHD1, TRIM5α, and BST2 referred to as restriction factors ([@B67]; [@B71]; [@B54]; [@B75]; [@B37]), but also they unraveled the importance of the accessory proteins of viruses in this process ([@B43]).

The genome of lentiviruses encodes for several accessory proteins such as Nef, Vif, Vpr, Vpx, and Vpu, in addition to the structural and enzymatic proteins Gag, Pol, and Env and the regulatory proteins Tat and Rev ([@B43]). These accessory proteins are, however, not common to all lentiviruses: Nef and Vpr are specific of primate lentiviruses (HIV-1, HIV-2, and SIV), Vpx is expressed by HIV-2 and its closely related SIV~smm~ and SIV~mac~, Vpu is expressed by HIV-1 strains and a few strains of SIV (described later; [@B44]). These proteins are not strictly required for viral replication *in vitro*. However, much evidence has highlighted their importance in the pathogenesis of the infection, as they contribute to modify the cell environment to facilitate viral replication and evasion from the host antiviral immune response ([@B44]).

This review will provide an overview of our current understanding of the mechanisms whereby the accessory protein Vpu exploits the host cell machineries to counteract two components of the adaptive and innate host immune system: the protein CD4 and the restriction factor BST2.

CHARACTERISTICS AND FUNCTIONS OF THE ACCESSORY PROTEIN VPU
==========================================================

The accessory protein Vpu is an 81-amino acid type I integral membrane phosphoprotein, expressed by the genome of HIV-1, the related SIV~cpz~ ([@B70]) and the SIV~gsn~ lineages including the greater spot-nosed monkey (SIV~gsn~), the mona monkey (SIV~mon~), the mustached monkey (SIV~mus~) and Dent's mona monkey (SIV~den~) isolates ([@B17]; [@B12], [@B11]; [@B2]). Vpu contains a short luminal N-terminal domain, a 23-amino acid transmembrane domain and a large cytoplasmic C-terminal domain ([@B70]; [@B42]). Vpu localizes mainly in the endoplasmic reticulum (ER), the *trans*--Golgi network (TGN) and endosomal compartments. Two major functions have been attributed to Vpu during HIV-1 replication cycle. Firstly, Vpu targets the newly synthesized CD4 receptor for proteasomal degradation ([@B79]). Secondly, it favors the release of viral particles from most human cell types through counteracting the inhibitory effect of BST2 ([@B54]; [@B75]). More recently, Vpu was shown to down-regulate cell surface expression of two additional mediators of the immune response: the lipid-antigen presenting protein CD1d expressed by antigen-presenting cells ([@B52]) and the natural killer cells ligand NTB-A ([@B66]). Vpu appears therefore as a key factor for HIV evasion from the host immune system.

VPU-INDUCED DOWN-REGULATION OF CD4
==================================

CD4 constitutes the major component of the receptor complex used by primate lentiviruses to infect the cells. It is a 54 kDa type I integral glycoprotein expressed at the surface of helper T-lymphocytes, cells of the monocyte/macrophage lineage and hematopoietic progenitor cells.

Infection of CD4^+^ cells by primate lentiviruses results in a rapid and constant down-modulation of cell surface CD4 expression level ([@B59]). CD4 down-regulation was proposed to prevent lethal superinfection of cells by additional virions ([@B78]), contribute to the escape of infected cells from the immune system and favor viral fitness ([@B80]). CD4 depletion in infected cells is achieved by the concerted, though mechanistically distinct, action of three viral proteins: Nef, Vpu and, to a lower extent, Env ([@B78]). Nef, produced shortly after infection, enhances internalization of pre-existing CD4 from the cell surface and targets the receptor for lysosomal degradation ([@B8]). Env precursor gp160 binds CD4 in the ER and blocks its transport to the cell surface ([@B13]; [@B29]). Vpu targets CD4 molecules present in the ER for proteasomal degradation ([@B79]).

Vpu induces degradation of newly synthesized CD4 by a multi-step process involving binding of Vpu with CD4 *via* their transmembrane domains (TMD), retention and poly-ubiquitination of CD4 in the ER, followed by its delivery to the ER-associated degradation pathway (ERAD) for further proteasomal degradation ([@B41]; [@B40]; **Figure [1](#F1){ref-type="fig"}**). Vpu-induced degradation of CD4 requires the integrity of two phosphoserines S~52~/S~56~ present in a canonical DSGXXS motif within the cytoplasmic tail of Vpu and involved in an interaction with the β-transducin repeat-containing protein 1 or 2 (β-TrCP1; β-TrCP2), two adaptors for the SKP1-cullin1-F-Box (SCF) E3 ubiquitin ligase complex ([@B46]). Recruitment of the SCF^β-TrCP^) complex by Vpu results in poly-ubiquitination of the cytoplasmic tail of CD4 on lysine, serine and threonine residues ([@B41]). Interestingly, Vpu-induced SCF-mediated poly-ubiquitination of CD4 contributes to retain the receptor in the ER and enables the recruitment of the ERAD VCP-UFD1L-NPL4 dislocase complex, leading to the extraction of CD4 from the ER membrane and its subsequent degradation by the proteasome ([@B41]; **Figure [1](#F1){ref-type="fig"}**).

![**Vpu mediates proteasomal degradation of CD4 to favor viral fitness. (A)** Newly synthetized CD4 and HIV-1 envelope precursor gp160 interact in the ER through their luminal domain, preventing Env trafficking to the cell surface. **(B)** Vpu induces retention of CD4 in the ER through interaction *via* their transmembrane region and connects CD4 to SKP1-cullin1-F-Box (SCF) E3 ubiquitin ligase through binding with the SCF subunits β-TrCP1 and β-TrCP2. Interaction of Vpu with β-TrCP involves the conserved phophorylated serines S~52~ and S~56~, located in the cytoplasmic tail of Vpu. Recruitment of the SCF^β-TrCP^ complex by Vpu induces poly-ubiquitination of CD4 on lysine, serine and threonine residues in its cytoplasmic tail. Poly-ubiquitination of CD4 partially contributes its retention in the ER, through a yet-to-be-determined mechanism. Vpu-induced SCF-mediated poly-ubiquitination of CD4 enables the recruitment of the ERAD VCP-UFD1L-NPL4 dislocase complex, leading to the extraction of CD4 from the ER membrane and its subsequent degradation by the proteasome. Degradation of CD4 by Vpu was proposed to dissociate CD4 from newly synthesized viral Env present in the ER, allowing Env maturation and trafficking to the cell surface for its subsequent incorporation in the forming virions.](fmicb-05-00177-g001){#F1}

VPU-MEDIATED ANTAGONISM OF THE RESTRICTION FACTOR BST2
======================================================

A major breakthrough in understanding how Vpu promotes the release of HIV-1 particles was made by the identification of BST2 as a restriction factor for HIV-1 release ([@B54]; [@B75]).

CHARACTERISTICS OF BST2
-----------------------

BST2 is a 30--36 kDa highly glycosylated type II integral membrane protein, constitutively expressed in several cell types and can be up-regulated by type-I interferon and pro-inflammatory stimuli ([@B53]). BST2 is composed of a short N-terminal cytoplasmic tail, linked to a transmembrane domain and an extracellular domain anchored to the membrane through a C-terminal glycosyl-phosphatidylinositol (GPI) moiety ([@B36]). Recently, a short isoform of BST2 produced by an alternative translation initiation from the methionine residue at position 13 has been identified ([@B10]). BST2 is localized at the plasma membrane (PM) in cholesterol--rich microdomains (rafts) and in intracellular compartments such as the TGN as well as early and recycling endosomes ([@B36]; [@B47]). BST2 was proposed to assemble as a "picket fence" around the lipid rafts, playing a role in organizing membrane microdomains ([@B4]). BST2 was shown to physically trap the *de novo* formed mature viral particles at the surface of infected cells, thereby considerably reducing virus release ([@B54]; [@B75]; [@B56]; [@B25]). This activity relies on BST2 ability to form parallel disulfide--bond homo-dimers and to bridge virions and cellular membranes *via* its N-- and C--terminal membrane anchoring domains ([@B28]; [@B56]; [@B63]), with a preference for an "axial" configuration in which the GPI anchors are inserted into virions, and the N-termini transmembrane anchors remain in the infected cells membrane ([@B76]).

Although initially identified as the factor responsible for defective release of HIV-1 mutants lacking the accessory gene *vpu* ([@B54]; [@B75]), it is now well established that BST2 restricts the release of nearly all enveloped viruses (retroviruses, herpes viruses, filoviruses, rhabdoviruses, paramyxoviruses, and arenaviruses) ([@B53]). BST2 therefore appears as a major mediator of the innate immune defense against viral dissemination. Primates lentiviruses deploy three proteins to antagonize BST2 antiviral activity: Vpu in HIV-1 ([@B54]; [@B75]); Env in HIV-2 ROD10, HIV-2 RODA, SIV~agm~Tan and SIV~mac239~Δ*nef* isolates ([@B22]; [@B39]; [@B26]; [@B65]) and Nef in most isolates of SIV ([@B32]; [@B61]; [@B81]). HIV-1 Vpu, HIV-2 Env, and SIV Nef were shown to down-regulate the cell surface expression level of BST2 to favor its removal from viral budding sites and further viral release ([@B53]). To date, the precise mechanism involved in this process has not been fully characterized.

BINDING OF VPU WITH BST2
------------------------

Binding of Vpu with BST2 through their respective TMD was shown to be essential to counteract BST2 antiviral activity. Mutagenesis analyzes have unraveled the critical role of residues I~34~, L~37~, L~41~ of BST2 and A~14~, W~22~ and to some extent A~18~ of Vpu in this interaction ([@B77]; [@B34]). These residues were proposed to form an anti-parallel helix-helix interface ([@B68]). Interestingly, recent studies have identified additional residues, located at the periphery of the TMD of BST2 and Vpu respectively, required for the interaction between both proteins and antagonism of BST2 ([@B49]; [@B57]).

VPU-INDUCED CELL SURFACE DOWN-REGULATION OF BST2
------------------------------------------------

The mechanism whereby Vpu decreases cell surface BST2 expression appears to rely on interference with BST2 intracellular trafficking. BST2 was thought to cycle between the PM, the TGN and the endosomes, with a fraction sorted for lysosomal degradation through an Endosomal Sorting Complexes Required for Transport (ESCRT)-mediated pathway ([@B60]; [@B47]; [@B24]; [@B30]). Internalization of BST2 from the PM occurs through clathrin-coated vesicles, *via* direct binding of the clathrin adaptor complexes AP2 with non-canonical dual tyrosine residues (Y~6~XY~8~) in the cytoplasmic tail of BST2 ([@B60]; [@B47]). Binding of BST2 with AP1 complexes regulates its retrieval from the early endosomes back to the TGN ([@B60]). Vpu does not increase the rate of BST2 endocytosis but rather slows down the recycling of internalized BST2 back to the PM and inhibits the access of *de novo* synthetized BST2 to the cell surface, thereby decreasing the resupply of BST2 to the PM ([@B50]; [@B15]; [@B38]; [@B62]; **Figure [2](#F2){ref-type="fig"}**).

![**Vpu subverts the host cell trafficking and ubiquitin machineries to counteract BST2 antiviral activity**. BST2 physically tethers HIV-1 particles on the surface of infected cells preventing their release and further dissemination. The accessory protein Vpu counteracts this restriction by hijacking the host machineries involved in BST2 trafficking and turnover. BST2 cycles between the plasma membrane, the TGN and the endosomes, with a fraction sorted for lysosomal degradation through an ESCRT-mediated pathway (left panel). Vpu counteracts BST2 restriction activity through (i) displacing it from viral assembly sites by a yet-to-be-determined mechanism involving a "dileucine"-like motif located in its cytoplasmic tail and (ii) down-regulating BST2 cell surface expression level and as such restores viral release. Vpu down-regulates cell surface BST2 by slowing down the PM access of internalized and newly synthesized BST2. Vpu-induced BST2 cell surface down regulation is associated with targeting of the restriction factor for lysosomal degradation through an ubiquitin-dependent mechanism that involves the recruitment of SCF^β-TrCP^ E3 ubiquitin ligase complex and the ESCRT machinery. Indeed, through binding to HRS, Vpu enhances the affinity of BST2 for HRS thus accelerating its sorting by the ESCRT machinery for lysosomal degradation. One might propose that through binding with the ESCRT machinery, Vpu may favor the sorting of BST2 at the level of endosomes, thereby reducing its recycling to the plasma membrane (right panel). This figure is adapted from [@B31].](fmicb-05-00177-g002){#F2}

In some cell types such as T-cells and primary macrophages, antagonism of BST2 by Vpu is not associated with decreased expression of cell surface BST2 ([@B51]; [@B9]), consistent with the view that Vpu promotes viral release by displacing BST2 from viral budding sites at the PM. Using a sophisticated approach, it has been recently suggested that this function relies on the integrity of a "dileucine"-like motif E~59~VSAL~63~V in the cytoplasmic tail of Vpu ([@B49]), first reported to be essential for Vpu to down-regulate CD4 and BST2 expression and counteract BST2 antiviral activity ([@B27]; [@B35]). How this motif contributes to these functions is, however unclear. Vpu EXXXLV motif fits the consensus dileucine -- based sorting signal (D/E)XXXL(L/I/M) that mediates binding to the AP complexes. However, evidence for an interaction of Vpu with the AP complexes or a direct contribution of these complexes in Vpu's functions could not be demonstrated ([@B35]).

VPU-MEDIATED DEGRADATION OF BST2
--------------------------------

In some cell types, Vpu-induced down-regulation of cell surface BST2 is associated with enhanced targeting of the cellular protein to the degradation pathway ([@B21]; [@B50]). This process is ubiquitin-dependent and requires the recruitment of the SCF^β-TrCP^ complex by Vpu *via* its DS~52~GxxS~56~ motif ([@B14]; [@B18]; [@B45]; [@B50]; [@B74]). The importance of β-TrCP in Vpu-mediated antagonism of BST2 antiviral activity remains controversial to date ([@B14]; [@B28]; [@B45]; [@B50]; [@B51]; [@B72]). BST2 undergoes ubiquitination on lysine residues located in its cytoplasmic tail ([@B55]). Interestingly, Vpu increases BST2 ubiquitination on lysine/serine and threonine residues located in its cytoplasmic tail, as is also observed with CD4 ([@B74]). Mutation of these residues reduces Vpu-induced antagonism of BST2. Consistent with this observation, the short isoform of BST2 lacking these residues shows decreased sensitivity to Vpu antagonism ([@B74]; [@B10]). One study challenged the requirement of the S~3~T~4~S~5~ residues in Vpu-induced ubiquitination of BST2 ([@B23]) but no explanation has been proposed for this discrepancy.

Despite the similarity in the molecular mechanisms underlying Vpu-induced ubiquitination and degradation of CD4 and BST2, the fate of both proteins differs. Indeed, it is now well established that Vpu does not target BST2 for proteasomal degradation but induces β-TrCP-dependent lysosomal sorting of BST2 ([@B14]; [@B28]; [@B50]). In agreement with this notion, we highlighted a major role of Rab7, a regulator of the endo/lysosomal trafficking, in this process ([@B6]), and revealed that Vpu enhances ESCRT-mediated sorting of BST2 for degradation ([@B30]). The ESCRT machinery is a set of four hetero-oligomeric protein complexes involved in the sorting of ubiquitinated membrane proteins into vesicles budding into endosomes for their subsequent degradation in the lysosomes. The ESCRT-0 protein HRS (hepatocyte growth factor-regulated tyrosine kinase substrate) coordinates this process by linking ubiquitinated cargoes and the ESCRT-I component TSG101 ([@B58]). We showed that Vpu-mediated down-regulation of BST2 and viral release require HRS, and unveiled an increased affinity of BST2 for HRS upon Vpu expression ([@B30]). One might propose that through binding with HRS and BST2, Vpu accelerates ESCRT-mediated sorting of BST2 to the lysosomes, thereby reducing its recycling to the PM ([@B31]; **Figure [2](#F2){ref-type="fig"}**). Further evidence of the requirement of the ESCRT machinery in Vpu-mediated BST2 degradation was obtained by the characterization of a new component of the ESCRT-I machinery: the protein UBAP1 ([@B1]). Depletion of UBAP1 abolishes Vpu-induced degradation of BST2, but has no impact on Vpu antagonism of BST2 antiviral activity ([@B1]), consistent with the notion that degradation of BST2 is not strictly required for Vpu-mediated antagonism of BST2 ([@B51]; [@B19]).

VPU AND BST2 VIRAL SENSING ACTIVITY
===================================

In addition to its activity as a restriction factor of viral release, BST2 has been recently characterized as an innate immune sensor for HIV ([@B10]; [@B16]; [@B73]). In 2003, BST2 was first reported to stimulate the activity of the NF-κB family of transcription factors, using a whole-genome cDNA screen ([@B48]). Recent studies further revealed that tethered HIV particles increase BST2 signaling activity, resulting in enhanced production of pro-inflammatory stimuli, consistent with a role of BST2 as a sensor for assembled viruses ([@B10]; [@B16]; [@B73]). This function seems separable from its activity as an inhibitor of viral release and relies on the integrity of the non-canonical dual tyrosine residues (Y~6~XY~8~) regulating its trafficking ([@B16]; [@B73]). Whether BST2 trafficking is relevant for its signaling activity is unclear. BST2 was proposed to activate the "canonical" NF-κB pathway through engaging mediators of this pathway *via* its tyrosine motif ([@B16]; [@B73]). Regulation of this pathway depends on the activation of the transforming growth factor-β-activated kinase-1 (TAK1)/TAK1-binding protein 1 and 2 (TAB1 and TAB2) complex, through poly-ubiquitination by E3 ligases of the TNF receptor-associated factors (TRAFs) family ([@B69]). Interestingly, BST2 was shown to co-immunoprecipitate with TRAF2, TRAF6 as well as the TAK1/TAB1 complex ([@B16]; [@B73]).

Vpu was shown to counteract BST2 signaling activity through a β-TrCP-dependent mechanism ([@B73]). Interestingly, over a decade ago, Vpu was shown to sequester β-TrCP away from its substrates and inhibit NF-κB activation by interfering with β-TrCP-mediated degradation of the NF-κB inhibitor IκB ([@B5]; [@B3]). Whether this mechanism accounts solely for Vpu-induced inhibition of BST2 signaling activity requires further investigation. Furthermore, many questions remain regarding how viral expression triggers BST2 sensing activity.

CONCLUDING REMARKS
==================

Over the past decade, Vpu has emerged as an important asset for viral egress and evasion from the host antiviral mechanisms. Although tremendous progress has been made toward understanding the mechanisms underlying Vpu's functions, many questions remain regarding how this protein contributes to viral pathogenesis. Vpu's contribution to viral immune evasion relies on its ability to alter the trafficking of its targets by subverting cellular machineries involved this process. However, despite some similarities in the mechanisms involved, major differences have been reported regarding the site of action of Vpu as well as the fate of its targets in cells. Further characterization of the mechanisms controlling Vpu expression and distribution in cells as well as the interplay with its targets and the host cell machineries might contribute to explain these pleiotropic effects. In keeping with this line of thought, another fascinating aspect worthy of further investigation is the role of Vpu with regards to BST2, in cell-to-cell transmission of HIV through virological synapses. So far, conflicting results have been obtained regarding the impact of both proteins on this process, but intriguingly, they have underlined a multifaceted role of BST2 in HIV pathogenesis ([@B64]; [@B20]; [@B7]; [@B33]). Adding to this complexity, BST2 was recently described to act as a host sensor of assembled viruses. Therefore, a more detailed characterization of BST2's functions in cells as well as its interplay with Vpu would contribute to better comprehend the role of both proteins in viral egress and dissemination. Addressing all these questions might provide important insights into AIDS pathogenesis and contribute to the future development of therapeutic strategies.
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